The cytokeratin network is an extensive fdamentous structure in the cytoplasm whose biological function (s Cytokeratin expression is a persistent phenotype which is used in diagnosing cancers, enabling identification of tumor type, metastatic tumor origin, and stage of disease (6).
ABSTRACT
The cytokeratin network is an extensive fdamentous structure in the cytoplasm whose biological function(s) is unknown. Based upon previous data showing the modification of cytokeratin by mitoxantrone, we investigated the ability of cytokeratin networks to influence the survival response of cells to chemotherapeutic agents. We have compared the survival of mouse L fibroblasts lacking cytokeratins with that of L cells transfected with cytokeratins 8 and 18 in the presence of chemotherapeutic drugs. The expression of cytokeratins 8 and 18 conferred a multiple drug resistance phenotype on cells exposed to mitoxantrone, doxorubicin, methotrexate, melphaIan, Colcemid, and vincristine. The degree of drug resistance was 5-454 times that of parental cells, depending upon the agent used. Drug resistance could not be attributed to altered growth characteristics, altered drug accumulation, or an altered drug efflux in the transfected cells. Cytokeratin does not confer resistance to ionizing radiation, which damages DNA independently of intracellular transport mechanisms. These data suggest a role for cytokeratin networks in conferring a drug resistance phenotype.
A major obstacle to successful cancer chemotherapy is tumor cell resistance to chemotherapeutic agents. Resistance may develop in response to selection pressure exerted by drug treatment or may be part of an inherent cellular response without prior treatment. In acquired resistance, a deviation from the normal cell phenotype occurs, and that deviation (for example, overexpression of the P-glycoprotein in multidrug resistance; ref. 1 Cytokeratin expression is a persistent phenotype which is used in diagnosing cancers, enabling identification of tumor type, metastatic tumor origin, and stage of disease (6) . Changes in the pattern of expression of cytokeratin during tumor progression can involve a reversion to the simple epithelial cytokeratins 8 and 18 (7) . These particular cytokeratins are also preferentially expressed in many carcinoma cell lines (6, 8) .
We utilized a mouse fibroblast cell line and a transfected variant expressing cytokeratins 8 and 18 (9) to test whether cytokeratin expression could alter the cell survival response to six different chemotherapeutic drugs.
MATERIALS AND METHODS
Tumor Cell Lines, Growth Curves, and Cell Cycle Distributions. Parental L cells and transfected LK8+18 cells were obtained from Robert Oshima (La Jolla Cancer Research Foundation, La Jolla, CA) and maintained as described (9) . Mock transfectants (LPBMOC) were created by simultaneous calcium phosphate transfection of pGEM-3 (Promega) and pSV2neo (10) To prepare cells for flow cytometric cell cycle analysis, cells were trypsinized and resuspended in DMEM. As resuspended cells were being gently vortexed, two volumes of a 3:1 solution of methanol/acetic acid were added to fix the cells prior to analysis. The suspension was then washed free of acid, treated with DNase-free RNase A (0.1 mg/ml) and stained with propidium iodide (100 jug/ml). Stained samples were stored refrigerated in the dark. Cell cycle analysis was performed as described (3) .
Drug Resistance Assays. Drug resistance was assayed by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma] dye assay (11) . Briefly, cells were plated in %-well plates in the presence of various chemotherapeutic agents. After 3 days, MTT dye was added to each well, and plates were incubated an additional 4 hr. After the contents of the wells were aspirated, dimethyl sulfoxide was added to the monolayers and plates were shaken for 5 12 ,000 x g and the pellet was dissolved for electrophoresis in an SDS/10%o polyacrylamide gel according to Laemmli (13) . Proteins were then transferred to nitrocellulose and incubated with antibody 10.11 (12) . Cytokeratin was visualized with a horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody and the ECL chemiluminescence detection kit (Amersham).
Colony Formation. Cells in logarithmic growth were subjected to yirradiation (6OCo) at doses ranging from 0 to 10 Gy. from cell to cell (Fig. 1A) . The parental L cells contained no detectable cytokeratin (Fig. 1C) (14) . Both probably cause DNA damage via formation of drug-dependent free radicals lower, but the LK8+18 cells were 454 times more resistant than the L cells. The LPBMOC cells appeared somewhat more sensitive to vincristine than the parental cells.
To determine whether cytokeratin conferred resistance to other DNA-damaging agents, both L and LK8+ 18 cells were irradiated with 6OCo, which directly damages DNA without requiring specific uptake, transport, and distribution processes. Radiation damage was scored by colony formation on plastic tissue culture plates. The fraction of LK8+18 cells surviving a dose of 2 Gy was lower than the corresponding surviving fraction of L cells. Cytokeratin did not confer resistance to radiation-induced cytotoxicity.
Drug Resistance Is Not Due to Altered Growth Characteristics in LK8+18 Cells. Neither the growth rate nor the distribution of LK8+18 cells within the cell cycle was different from that of the parental cells (Fig. 2) Likewise, the intracellular drug levels at various times after initiation of efflux measurements were similar, as were drug efflux rates for both mitoxantrone and doxorubicin (Fig. 3) At this time, it is unknown whether the de novo drug resistance is conferred by cytokeratins or requires the coexpression of cytokeratin and the endogenous vimentin intermediate-filament proteins in the transfected cells. Further, it is unknown whether the mechanism(s) involved in the cytokeratin-dependent drug resistance phenotype are similar for all the drugs tested. Our current working hypothesis is that the cytokeratin networks may influence the intracellular drug distribution so that particular nuclear targets are spared. Alternatively, since cytokeratin networks interact with the nucleus, the processing and repair of bulky nuclear damage may be influenced by cytoplasmic structure (18, 19) .
In addition to elucidating the mechanism responsible for the de novo drug resistance, it will be of interest to test whether the disruption of cytokeratin networks will sensitize human breast cancer cells to chemotherapeutic agents. Although mitoxantrone is effective in the treatment of hematologic malignancies, de novo drug resistance is a major factor limiting the treatment of epithelial-type malignancies such as breast cancer. The disruption of the cytokeratin networks which are present in breast cancer cells may remove the de novo drug resistance phenotype.
